Reata Reacquires Rights for Bardoxolone, Other Nrf2 Activators, After Terminating Partnership with AbbVie
Reata Pharmaceuticals has reacquired development, manufacturing, and marketing rights for its proprietary Nrf2 activator products — including bardoxolone methyl (bardoxolone) for the treatment of Alport syndrome and omaveloxolone for Friedreich’s ataxia — the company announced. This follows the termination of a partnership with…